Hyperfine Past Earnings Performance
Past criteria checks 0/6
Hyperfine's earnings have been declining at an average annual rate of -19%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 82.4% per year.
Key information
-19.0%
Earnings growth rate
67.1%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 82.4% |
| Return on equity | -52.4% |
| Net Margin | -401.0% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Hyperfine appoints Maria Sainz as President, CEO
Oct 06Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M
Aug 10Hyperfine stock plunges 14% as CEO Dave Scott steps down
Jun 29Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans
Apr 04
Hyperfine: MR Imaging In A Swoop
Mar 09Revenue & Expenses BreakdownBeta
How Hyperfine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 11 | -44 | 30 | 22 |
| 30 Sep 23 | 10 | -47 | 32 | 22 |
| 30 Jun 23 | 10 | -49 | 32 | 23 |
| 31 Mar 23 | 8 | -62 | 40 | 25 |
| 31 Dec 22 | 7 | -73 | 47 | 28 |
| 30 Sep 22 | 6 | -86 | 55 | 32 |
| 30 Jun 22 | 4 | -89 | 58 | 31 |
| 31 Mar 22 | 3 | -81 | 50 | 30 |
| 31 Dec 21 | 1 | -65 | 38 | 26 |
| 30 Sep 21 | 1 | -46 | 24 | 21 |
| 30 Jun 21 | 1 | -35 | 17 | 18 |
| 31 Mar 21 | 1 | -26 | 10 | 15 |
| 31 Dec 20 | 0 | -23 | 8 | 15 |
Quality Earnings: HYPR is currently unprofitable.
Growing Profit Margin: HYPR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HYPR is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare HYPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HYPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).
Return on Equity
High ROE: HYPR has a negative Return on Equity (-52.42%), as it is currently unprofitable.